# Real-World Evidence: Longitudinal Pain Interference &#038; Opioid Sparing across 32,000+ Clinical Encounters

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/rwe-chronic-pain-opioid-reduction-registry-analysis-2/
> **Published:** 2026-10-19T10:13:36-04:00 | **Last Modified / Clinically Audited:** 2026-10-19T10:13:36-04:00
> **Clinical Summary:** CED Clinic Clinical Registry Real-World Evidence (RWE) CEBM Level 2B: Clinical Registry Cohort Published: October 18, 2026 Real-World Evidence: Longitudinal Pain Interference &#038; Opioid Sparing across 32,000+ Clinical Encounters Longitudinal real-world evidence from the CED Clinic clinical registry evaluating symptom trajectory, tolerance prevention, and opioid reduction protocols across outpatient cohorts. Derived from longitudinal physician evaluations [&hellip;]

---

CED Clinic Clinical Registry
 Real-World Evidence (RWE)
 CEBM Level 2B: Clinical Registry Cohort
 Published: October 18, 2026
 

 
 

Table of Contents

- [Real-World Evidence: Longitudinal Pain Interference & Opioid Sparing across 32,000+ Clinical Encounters](#Real-World_Evidence_Longitudinal_Pain_Interference_038_Opioid_Sparing_across_32000_Clinical_Encounters)[Methodology & Observational Grounding](#Methodology_Observational_Grounding)[What does real-world evidence show regarding cannabinoids for Chronic Pain & Neuropathy?](#What_does_real-world_evidence_show_regarding_cannabinoids_for_Chronic_Pain_038_Neuropathy)
- [What is the clinical scale and data provenance of this Chronic Pain & Neuropathy analysis?](#What_is_the_clinical_scale_and_data_provenance_of_this_Chronic_Pain_038_Neuropathy_analysis)
- [Related](#Related)

# Real-World Evidence: Longitudinal Pain Interference & Opioid Sparing across 32,000+ Clinical Encounters

 

Longitudinal real-world evidence from the CED Clinic clinical registry evaluating symptom trajectory, tolerance prevention, and opioid reduction protocols across outpatient cohorts. Derived from longitudinal physician evaluations across 81,008 unique clinical cohorts and 130,447 structured follow-up encounters at CED Clinic, informed by Dr. Benjamin Caplan’s career oversight of 350,000+ patient evaluations.

 
 
 **Principal Investigator:** [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/)
 •
 Board-Certified Family Medicine (ABFM)
 
 

 
 
 81,008
 Patient Cohorts
 
 
 130,447
 Clinical Encounters
 
 
 91.4% High Compliance
 Protocol Adherence
 
 
 68.2%
 Tincture / Oral Route
 
 

 
 

### Methodology & Observational Grounding

 

Unlike traditional pharmaceutical clinical trials that restrict inclusion criteria to single-diagnosis participants devoid of concurrent medications, the **CED Clinic Real-World Evidence Registry** captures the complex clinical reality of outpatient cannabinoid medicine. Patients in this cohort were systematically evaluated under board-certified physician supervision, with structured longitudinal tracking of symptom burden, medication de-escalation, adverse event incidence, and chemovar responsiveness.

 

**Ethical Oversight & Data Governance:** Observational registry analyses synthesize de-identified clinical records adhering strictly to HIPAA Safe Harbor de-identification standards (45 CFR § 164.514(b)) and satisfy criteria for secondary research exemption under HHS Common Rule 45 CFR § 46.104(d)(4). No patient health identifiers are stored or disclosed.

 

 
 
 Clinical Translation — Benjamin Caplan, MD
 
 

*“Real-world registry data demonstrates that optimal opioid-sparing analgesia is achieved not by escalating single-molecule THC concentrations, but through consistent daytime anti-inflammatory tone (CBD/CBG) combined with precise, low-dose nighttime micro-titration to restore restorative slow-wave sleep.”*

 
 **Dr. Benjamin Caplan, MD** has supervised over 350,000 patient evaluations across his clinical career, including serving as Chief Medical Officer of Canna Care Docs (250,000+ patients) and founder of CED Clinic. He is the author of *The Doctor-Approved Cannabis Handbook* and architect of the 125,000+ study CED Command Center literature vault.
 
 

 
 
 
 Clinical Direct Answers & Evidence Summary
 
 
 

#### What does real-world evidence show regarding cannabinoids for Chronic Pain & Neuropathy?

 

Real-world registry data demonstrates that optimal opioid-sparing analgesia is achieved not by escalating single-molecule THC concentrations, but through consistent daytime anti-inflammatory tone (CBD/CBG) combined with precise, low-dose nighttime micro-titration to restore restorative slow-wave sleep.

 
 
 

#### What is the clinical scale and data provenance of this Chronic Pain & Neuropathy analysis?

 

This analysis synthesizes real-world clinical observations from Dr. Benjamin Caplan, MD, who has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). The specific dataset reflects 81,008 outpatient cohorts and 130,447 structured clinical visits tracked in the CED Clinic Clinical Registry.

 
 

 
 
 
 
 
 Clinical Surveillance & Registry Audit
 
 Surveillance Interval: Bi-Annual
 
 
 **Registry Cohort Release:** October 2026
 **Clinical Audit Status:** Active (October 2026)
 **Principal Investigator:** Benjamin Caplan, MD (ABFM)
 **Next Scheduled Extraction:** April 2027
 
 

 
 
 
 Academic & Clinical Citation Format (AMA)
 Oxford CEBM Evidence Level 2B
 
 
 Caplan B. Real-World Evidence: Longitudinal Pain Interference & Opioid Sparing across 32,000+ Clinical Encounters. *CED Clinic Real-World Observational Clinical Registry*. Published October 2026. https://cedclinic.com/rwe-chronic-pain-opioid-reduction-registry-analysis/
 
 

 
 [View Dr. Caplan’s CV & Research →](https://cedclinic.com/drcaplan/)
 [Physician Referral Portal →](https://cedclinic.com/physician-referral/)
 [Executive Advisory →](https://cedclinic.com/advisor/)
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
